{"id":"W4366603286","doi":"10.1080/10428194.2023.2196593","title":"Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy","year":2023,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Genentech; Servier; Astellas Pharma; Galecto; Sierra Oncology; CTI Biopharma; Incyte; Pfizer; CareDx; MorphoSys; Celgene; Bristol-Myers Squibb; AstraZeneca; Constellation Pharmaceuticals; Italfarmaco; Menarini Group; Astellas Pharma US; Gilead Sciences; U.S. Department of Defense","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Myeloproliferative neoplasm; Clinical trial; Janus kinase; Expanded access; Internal medicine; Oncology; Bone marrow; Cytokine","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.001646442,0.001658522,0.009224053,0.0005261546,0.0001702774,0.00009072254,0.0005286557,0.001537723,0.0001201276],"category_scores_gemma":[0.0013684,0.001281061,0.003737237,0.001003021,0.0005361746,0.0001432632,0.0004004289,0.0003497388,0.0003042902],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003201572,"about_ca_system_score_gemma":0.01074934,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001690811,"about_ca_topic_score_gemma":0.00001092246,"domain_scores_codex":[0.9905502,0.0005207324,0.004493889,0.002179992,0.0009978822,0.001257287],"domain_scores_gemma":[0.9922928,0.00286446,0.001829449,0.001657418,0.0004094829,0.0009464098],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000472957,0.000456357,0.0002899837,0.1773382,0.001969497,0.0003912969,0.00008152606,1.057003e-7,2.424944e-7,0.0002945428,0.009355881,0.8093494],"study_design_scores_gemma":[0.01106088,0.0009835447,0.008070043,0.204617,0.008270303,0.0006885016,0.00002688489,0.0000290224,0.000007514735,0.00004341863,0.7652758,0.0009270119],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.004382237,0.9857004,0.00001070292,0.0000989379,0.0007000539,0.006910394,0.0009315882,0.0002731027,0.0009925355],"genre_scores_gemma":[0.0002155257,0.9868562,0.00159575,0.001331936,0.001372878,0.004525268,0.001441002,0.0004421577,0.002219267],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.8084223,"threshold_uncertainty_score":0.9997585,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07429801613504322,"score_gpt":0.3947768205150981,"score_spread":0.3204788043800549,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}